Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Nebulised granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis.
Eur Respir Rev. 2023 Nov 22;32(170):230080. doi: 10.1183/16000617.0080-2023. Print 2023 Dec 31.
Eur Respir Rev. 2023.
PMID: 37993127
Free PMC article.
Review.
BACKGROUND: Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired macrophage-mediated clearance of alveolar surfactant lipoproteins. ...
BACKGROUND: Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired macrophage-mediated clearance …
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Lazarus HM, Ragsdale CE, Gale RP, Lyman GH.
Lazarus HM, et al.
Front Immunol. 2021 Aug 17;12:706186. doi: 10.3389/fimmu.2021.706186. eCollection 2021.
Front Immunol. 2021.
PMID: 34484202
Free PMC article.
Further, sargramostim therapy has been promising in the adjuvant setting with vaccines and for anti-microbial-resistant infections and treating autoimmune pulmonary alveolar proteinosis and gastrointestinal, peripheral arterial and neuro-inflammatory d …
Further, sargramostim therapy has been promising in the adjuvant setting with vaccines and for anti-microbial-resistant infections and treat …
Item in Clipboard
Cite
Cite